该项收购完成后,Cambrex公司将获得Avista公司包括从原料药、药品开发、环化核苷酸制造,到独立分析、微生物测验以及固态科学等多项服务,同时将Avista的4个制药站点纳入其生...查看全文
琬麟2015-02-07 09:21
$凯姆布雷克斯(CBM)$ EAST RUTHERFORD, N.J., Feb. 6, 2015 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM, "Cambrex") is pleased to announce that it has initiated the second significant expansion of its Charles City, Iowa facility in less than three years. Strong continu...查看全文
$凯姆布雷克斯(CBM)$ 美东时间 2018-08-02 盘前 披露财报,预期EPS 0.66 网页链接
$凯姆布雷克斯(CBM)$ 8-K - Current report Filed: 2018-07-23 AccNo: 0001193125-18-223081 Size: 4 MBItem 1.01: Entry into a Material Definitive AgreementItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$凯姆布雷克斯(CBM)$ 内部交易: 2018-06-11,总裁 & CEO,KLOSK STEVEN M ,卖出,55000普通股, $45.64
$凯姆布雷克斯(CBM)$ 内部交易: 2018-06-11,总裁 & CEO,KLOSK STEVEN M ,期权,55000普通股, $12.46
$凯姆布雷克斯(CBM)$ 内部交易: 2018-05-08,EVP & COO,Cavanagh Shawn ,卖出,19745普通股, $49.58
$凯姆布雷克斯(CBM)$ 内部交易: 2018-05-07,EVP & COO,Cavanagh Shawn ,卖出,20255普通股, $49.80
$凯姆布雷克斯(CBM)$ 内部交易: 2018-05-08,EVP, Corporate Development,SARGEN GREGORY ,卖出,44498普通股, $49.49
$凯姆布雷克斯(CBM)$ 内部交易: 2018-05-07,EVP, Corporate Development,SARGEN GREGORY ,卖出,23002普通股, $49.46
$凯姆布雷克斯(CBM)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2018-05-03 AccNo: 0001564590-18-010486 Size: 5 MB 网页链接
$凯姆布雷克斯(CBM)$ 8-K - Current report Filed: 2018-05-03 AccNo: 0001564590-18-010482 Size: 1 MBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接